Physix FrontierPhysix Frontier · News Briefing Card (enbrief · Sep 22, 2026)
AI drug discovery draws dense capital and policy backing as Insilico deals near $10B
KEY FACTS
- Several major events landed within a single week: Anew Labs raised $290 million, and Novo Nordisk struck a partnership with Anthropic.
- Insilico Medicine disclosed nearly $10 billion in total external collaborations for 2026, far exceeding its revenue scale in the previous fiscal year.
- China's first AI-assisted drug, Aipusiwei, won marketing approval, marking AI's formal entry into the drug approval process.
- GenScript plans to raise about HK$2.3 billion, with 70% of the proceeds earmarked for expanding AI-driven high-throughput wet labs.
KEY DATA
$290 millionAnew Labs angel round
nearly $10 billionInsilico Medicine 2026 total collaborations
about HK$2.327 billionGenScript placement net proceeds
98.4 mLRentosertib Phase 2 FVC improvement
PHYSIX OBSERVATION
AI drug discovery is shifting from "model showmanship" to "systematic output," and the core bottleneck has moved from algorithms and compute to the scale and standardization of wet-lab validation. The industry's competitive focus has become building a "dry-wet-data" closed-loop capability; whoever can deliver reproducible experimental feedback at low cost and high speed will hold pricing power. Companies that merely hold models or pipelines will be revalued, while platform service providers with infrastructure attributes and pharma companies with real clinical data will become the new winners.
Source: enbrief original report ↗